PLRX analyst estimates
Pliant Therapeutics (PLRX) analyst ratings, the average price target and its range, and every firm's latest call.
- 2 firms rate PLRX: 1 buy, 1 hold, 0 sell.
- The average price target is $3.00 from None analysts, from $3.00 to $3.00.
PLRX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Mar 12, 2026 | Piper Sandler | Pliant Therapeutics (PLRX) PT Lowered to $3 at Piper Sandler | $3.00 |
| Mar 3, 2025 | Leerink Partners | Pliant Therapeutics downgraded to Market Perform from Outperform at Leerink | $2.00 |
| Mar 3, 2025 | Stifel Nicolaus | Pliant Therapeutics downgraded to Hold from Buy at Stifel | $3.00 |
| Sep 13, 2024 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Pliant Therapeutics (PLRX) | $38.00 |
| Sep 9, 2024 | Leerink Partners | Pliant Therapeutics assumed with an Outperform at Leerink | $33.00 |
| May 23, 2024 | Piper Sandler | Piper Sandler Reiterates Overweight Rating on Pliant Therapeutics (PLRX) | $40.00 |
| May 7, 2024 | RBC Capital | Pliant Therapeutics (PLRX) PT Lowered to $45 at RBC Capital | $45.00 |
| May 7, 2024 | H.C. Wainwright | Pliant Therapeutics (PLRX) PT Lowered to $36 at H.C. Wainwright | $36.00 |
| May 7, 2024 | Oppenheimer | Pliant Therapeutics (PLRX) PT Raised to $48 at Oppenheimer | $48.00 |
| May 7, 2024 | Stifel Nicolaus | Pliant Therapeutics (PLRX) PT Lowered to $32 at Stifel | $32.00 |
| Dec 7, 2022 | J.P. Morgan | JP Morgan Initiates Coverage On Pliant Therapeutics with Overweight Rating, Announces Price Target of $42 | $42.00 |